A phase II randomised trial of second-line treatment in patients with small cell lung cancer (SCLC), comparing oral combination chemotherapy (CCNU [lomustine, idarubicin, dexamethasone], cyclophosphamide, etoposide) with intravenous combination chemotherapy.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics; Cyclophosphamide; Etoposide; Lomustine
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

09 Mar 2010 Biomarkers information updated
15 Sep 2009 Planned end date changed from 1 Sep 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
19 Jan 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight